Exelixis, Inc. Announces Fourth Quarter And Full Year 2013 Financial Results

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and year ended December 31, 2013.

Q4 2013 Highlights and Recent Events

•Completed enrollment in COMET-1, the phase 3 study of cabozantinib versus prednisone with the primary endpoint of overall survival in patients with advanced metastatic castration-resistant prostate cancer (CRPC).

Help employers find you! Check out all the jobs and post your resume.

Back to news